摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1,4,7b-triazacyclopenta[cd]inden-2-thiol | 333986-55-3

中文名称
——
中文别名
——
英文名称
1,4,7b-triazacyclopenta[cd]inden-2-thiol
英文别名
2,6,11-triazatricyclo[5.3.1.04,11]undeca-1(10),4,6,8-tetraene-3-thione
1,4,7b-triazacyclopenta[cd]inden-2-thiol化学式
CAS
333986-55-3
化学式
C8H5N3S
mdl
——
分子量
175.214
InChiKey
ALGQEKVQFKBFSY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    61.4
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Cyclic amine compounds as CCR5 antagonists
    摘要:
    式(I)的化合物(其中R1是氢原子,可能被取代的碳氢基团,可能被取代的非芳香杂环基团,R2是可能被取代的碳氢基团,可能被取代的非芳香杂环基团,或R1和R2可以彼此结合与A一起形成可能被取代的杂环基团;A是N或N+—R5.Y−(R5是碳氢基团;Y−是一个对离子);R3是可能被取代的环烃基团或可能被取代的杂环基团;n为0或1;R4是氢原子,可能被取代的碳氢基团,可能被取代的杂环基团,可能被取代的烷氧基团,可能被取代的芳基氧基团,或可能被取代的氨基团;E是可能被除氧以外的基团取代的二价脂肪族碳氢基团;G1是键,CO或SO2;G2是CO,SO2,NHCO,CONH或OCO;J是亚甲基或氮原子;Q和R中的每一个是键或可能被取代的二价C1-3脂肪族碳氢基团;条件是当G2为OCO时J为亚甲基,当另一个为键时Q和R中的一个不是键,当G1为键时Q和R中的每一个都不被氧基取代)或其盐具有强大的CCR5拮抗活性,并可优势用于治疗或预防人类体内各种HIV引起的传染病(例如艾滋病)。
    公开号:
    US06562978B1
点击查看最新优质反应信息

文献信息

  • [EN] CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS<br/>[FR] COMPOSES D'AMINE CYCLIQUE UTILISES COMME ANTAGONISTES DE CCR5
    申请人:TAKEDA CHEMICAL INDUSTRIES LTD
    公开号:WO2001025200A1
    公开(公告)日:2001-04-12
    A compound of formula (I) (wherein R1 is a hydrogen atom, a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, R2 is a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, or R?1 and R2¿ may combine to each other together with A to form a heterocyclic group which may be substituted; A is N or N?+-R5 •Y-(R5¿ is a hydrocarbon group; Y- is a counter anion); R3 is a cyclic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; n is 0 or 1; R4 is a hydrogen atom, a hydrocarbon group which may be substituted, a heterocyclic group which may be substituted, an alkoxy group which may be substituted, an aryloxy group which may be substituted, or an amino group which may be substituted, E is a divalent aliphatic hydrocarbon group which may be substituted by group(s) other than oxo; G1 is a bond, CO or SO¿2; G?2 is CO, SO¿2?, NHCO, CONH or OCO; J is methine or a nitrogen atom; and each of Q and R is a bond or a divalent C1-3 aliphatic hydrocarbon which may be substituted; provided that J is methine when G2 is OCO, that one of Q and R is not a bond when the other is a bond and that each of Q and R is not substituted by oxo group(s) when G?1¿ is a bond) or a salt thereof has a potent CCR5 antagonistic activity and can be advantageously used for the treatment or prevention of infectious disease of various HIV in human (e.g. AIDS).
    化合物式为(I)(其中R1是氢原子,可被取代的碳氢基团,可被取代的非芳香杂环基团,R2是可被取代的碳氢基团,可被取代的非芳香杂环基团,或R1和R2可以与A一起结合形成可被取代的杂环基团;A是N或N+ -R5 • Y-(R5是碳氢基团;Y-是反离子);R3是可被取代的环烃基团或可被取代的杂环基团;n为0或1;R4是氢原子,可被取代的碳氢基团,可被取代的杂环基团,可被取代的烷氧基,可被取代的芳氧基,或可被取代的氨基,E是可被除氧基以外的基取代的二价脂肪烃基团;G1是键,CO或SO2;G2是CO,SO2,NHCO,CONH或OCO;J是甲基或氮原子;Q和R中的每一个都是一个键或一个可被取代的二价C1-3脂肪基团;前提是当G2是OCO时,J是甲基,当另一个是键时,其中一个不是键,当G1是键时,Q和R中的每一个都没有被氧基团取代)或其盐具有强效的CCR5拮抗活性,并可用于人类各种HIV感染疾病(例如艾滋病)的治疗或预防。
  • Cyclic Amine Compounds as CCR5 Antagonists
    申请人:Takeda Pharmaceutical Company Limited
    公开号:EP1886994A1
    公开(公告)日:2008-02-13
    A compound of the formula: (wherein R1 is a hydrogen atom, a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, R2 is a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, or R1 and R2 may combine to each other together with A to form a heterocyclic group which may be substituted; A is N or N+-R5 . Y- (R5 is a hydrocarbon group; Y- is a counter anion) ; R3 is a cyclic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; n is 0 or 1; R4 is a hydrogen atom, a hydrocarbon group which may be substituted, a heterocyclic group which may be substituted, an alkoxy group which may be substituted, an aryloxy group which may be substituted, or an amino group which may be substituted, E is a divalent aliphatic hydrocarbon group which may be substituted by group (s) other than oxo;G1 is a bond, CO or SO2 ; G2 is CO,S02, NHCO, CONH or OCO ; J is methine or a nitrogen atom; and each of Q and R is a bond or a divalent C1-3 aliphatic hydrocarbon which may be substituted; provided that J is methine when G2 is OCO, that one of Q and R is not a bond when the other is a bond and that each of Q and R is not substituted by oxo group (s) whenGo ils a bond) or a salt thereof has a potent CCR5 antagonistic activity and can be advantageously used for the treatment or prevention of infectious disease of various HIV in humans (e.g. AIDS).
    式中的化合物: (其中 R1 是氢原子、可被取代的烃基、可被取代的非芳香杂环基团,R2 是可被取代的烃基、可被取代的非芳香杂环基团,或 R1 和 R2 可与 A 相互结合形成可被取代的杂环基团;A 是 N 或 N+-R5 .Y-(R5 是烃基;Y- 是反阴离子);R3 是可被取代的环烃基或可被取代的杂环基;n 是 0 或 1;R4 是氢原子、可被取代的烃基、可被取代的杂环基、可被取代的烷氧基、可被取代的芳氧基或可被取代的氨基;E 是可被除氧代以外的基团(s)取代的二价脂肪族烃基;G1 是键、CO 或 SO2;G2 是 CO、S02、NHCO、CONH 或 OCO;J 是甲烷或氮原子;Q 和 R 各自是键或可被取代的二价 C1-3 脂肪族烃;条件是:当 G2 为 OCO 时,J 为甲烷;当另一个为键时,Q 和 R 中的一个不是键;当 Go ils 为键时,Q 和 R 中的每一个没有被氧化基团(s)取代)或其盐具有强效的 CCR5 拮抗活性,可有利地用于治疗或预防人类各种 HIV 感染性疾病(如艾滋病)。例如艾滋病)。
  • CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS
    申请人:Takeda Chemical Industries, Ltd.
    公开号:EP1220842A1
    公开(公告)日:2002-07-10
  • US6562978B1
    申请人:——
    公开号:US6562978B1
    公开(公告)日:2003-05-13
  • US7348324B2
    申请人:——
    公开号:US7348324B2
    公开(公告)日:2008-03-25
查看更多

同类化合物

3H-1,4,8B-三氮杂苊烯e-3,5(4H)-二酮 3,4-bis(hydroxymethyl)dipyrido[1,2-a;3',4'-d]imidazole 3-methyldipyrido[1,2-a;3',4'-d]imidazole 2-methyl-6,7,8,9-tetrahydropyrido<1,2-a>benzimidazole 6,7,8,9-tetrahydrobenzo[4,5] imidazo[1,2-a]pyridin-3-amine 3-bromo-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridine N-[1-[3-(3-cyanophenyloxy)propan-1-yl]piperidin-4-yl]-5-thia-1,8b-diazaacenaphthylene-4-carboxamide N-[1-[3-(2-cyanophenyloxy)propan-1-yl]piperidin-4-yl]-5-thia-1,8b-diazaacenaphthylene-4-carboxamide 4,5-dihydro-4-[4-(tert-butoxycarbonylamino)butan-1-yl]-3H-1,4,8b-triazaacenaphthylene-3,5-dione diethyl 5-hydroxy-3-thia-1,8b-diazaacenaphthylene-2,4-dicarboxylate 5-thia-1,8b-diazaacenaphthylene-4-carbaldehyde 2-bromo-7,8-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-9(6H)-one 2-(2-morpholinopyrimidin-5-yl)-7,8-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-9(6H)-one 9H-imidazo[1,2-a]pyrrolo[2,3-c]pyridine 8-chloro-1-[2-(difluoromethoxy)phenyl]-3,4-dihydro-1H-pyrano[4',3':4,5]imidazo[1,2-a]pyridine 6-methoxymethyl-2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydro-imidazo[2,1-a]isoquinoline 4,5-dihydro-4-(tert-butoxycarbonyl)-3H-1,4,8b-triazaacenaphthylen-3-one imidazo<4',5':4,5>imidazo<1,2-a>pyridine">1,10-diethylpyrido<1",2":1',2'>imidazo<4',5':4,5>imidazo<1,2-a>pyridine imidazo<4',5':4,5>imidazo<1,2-a>pyridine">1,10-dimethylpyrido<1",2":1',2'>imidazo<4',5':4,5>imidazo<1,2-a>pyridine 1,3,4-trifluoro-dipyrido[1,2-a;3',4'-d]imidazole 3-(cyclopropyl)pyrano[3',4':4,5]imidazo[1,2-a]pyridinone 3-[(N-benzyl-N-methylamino)methyl]pyrano-[3',4':4,5]imidazo[1,2-a]pyridin-1-one 2-chloro-8-hydroxymethylene-6,7,8,9-tetrahydropyrido[1,2-a]benzimidazol-9-one ethyl 7-nitro-1H-imidazo<1,2-a>pyrazolo<3,4-c>pyridine-8-carboxylate 1-oxopyrido(1',2':1,2)imidazo[5,4-d]-1,2,3-triazine 3-methyl-2-[5-(amino)pentan-1-ylthio]-1,4,7b-triazacyclopent[cd]indene 1-methyl-3-pentyldipyrido[1,2-a:3',4'-d]imidazole 3-cyclopropyl-1-methyldipyrido[1,2-a:3',4'-d]imidazole 8-oxo-2,7,9-trimethylimidazo<4.5-c>imidazo<1.2-a>pyridine 1,3,7b-triazacyclopentinden-4(3H)-one 2-(2'-adamantyl)-8-oxo-7,9-dimethylimidazo<4.5-c>imidazo<1.2-a>pyridine ((7R,8S)-3-(1,3,4-oxadiazol-2-yl)-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-yl)carbamate (7R,8S)-3-(1,2,4-oxadiazol-5-yl)-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-amine tert-butyl ((7R,8S)-3-(1H-tetrazol-5-yl)-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-yl)carbamate tert-butyl ((7R,8S)-3-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-yl)carbamate tert-butyl ((7R,8S)-3-(2-methyl-2H-tetrazol-5-yl)-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-yl)carbamate (7R,8S)-3-(2-methyl-2H-tetrazol-5-yl)-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-amine 5-((7R,8S)-8-amino-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-3-yl)-3-methyl-1,3,4-oxadiazol-2(3H)-one tert-butyl ((7R,8S)-3-(4-methyl-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-yl)carbamate tert-butyl ((7R,8S)-3-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-yl)carbamate 5-((7R,8S)-8-amino-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-3-yl)-1,2,4-oxadiazol-5(4H)-one tert-butyl ((7R,8S)-3-((Z)-carbamohydrazonoyl)-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-yl)carbamate (7R,8S)-8-amino-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (7R,8S)-3-(1,2,4-oxadiazol-3-yl)-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-amine 3-((7R,8S)-8-amino-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-3-yl)-4-methyl-1,2,4-oxadiazol-5(4H)-one ((7R,8S)-3-(1H-tetrazol-5-yl)-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-yl)carbamate (7R,8S)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-amine tert-butyl ((7R,8S)-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-yl)carbamate tert-butyl ((7R,8S)-3-cyano-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-yl)carbamate (7R,8S)-3-(1,3,4-oxadiazol-2-yl)-7-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-amine